Presentations

Showing 1–12 of 25 results

Presentations [SBS 2009] Cell-based Receptor Tyrosine Kinase Screening Reloaded – Development of a new cellular assay system for a target protein so far resistant against HTS formats

Read More
Presentations [PEGS 2023] Accelerating Immuno-Oncology Drug Discovery with MOA-Reflective, Functional Cell-Based Assays

Venkatesh Chari, Ph.D. Scientific Market Development Manager Eurofins DiscoverX Products LLC

Read More
Presentations [EU PEGS 2022] Implementing MOA-Reflective Cytotoxicity Assays Using Ready-to-Use KILR®Target & Effector Cells from Screening to Lot Release

Andrew Green Sr. Business Development Manager

Read More
Presentations [Biophysical Society 2023] Characterization of Two Eurofins DiscoverX’s PrecisION® Nicotinic Cell Lines Using Automated Electrophysiology

Drug Discovery for Ion Channels XXIII Satellite Meeting

Read More
Presentations [Immuno-Oncology Summit 2021] Accelerating Immunotherapy Drug Development with Simple Cell-Based Assays for Immune Checkpoint Receptors

Jennifer Lin-Jones, Ph.D. Senior Group Leader, Assay Development

Read More
Presentations Using DiscoverX’s ADP QuestTM for Academic Screening of Novel Kinases

Read More
Presentations [WCBBA 2022] Accelerating Potency Bioassay Implementation from Development to QC Lot-Release & Ensuring Long-term Assay Reproducibility

Alpana Prasad, Ph.D. Director, Innovations and Strategic Partnership

Read More
Presentations [WCB 2020] Accelerate Your COVID-19 Drug Discovery with Qualified Cell-Based Assays for Proinflammatory Cytokines

Gaurav Agrawal, Ph.D. Scientific Development Manager, Eurofins DiscoverX

Read More
Presentations [PEGS 2022] Implementing MOA-Reflective ADCC Assays using Ready-to-Use KILR Target and Effector Cells from Screening to Lot Release

Gaurav Agrawal, Ph.D.Scientific Development Manager

Read More
Presentations [PEGS 2021] Accelerating Development of Therapeutic Interventions for COVID-19

Gaurav Agrawal, Ph.D. Scientific Development Manager Abstract Millions of deaths worldwide have been attributed to COVID-19, caused by the SARS-CoV-2…

Read More
Presentations [PEGS 2017] Enabling Technologies for Development and Optimization of Bi-Specific Antibodies for T Cell Redirection

DiscoverX PEGS 2017 Presentation Presented By: Jane Lamerdin, Ph.D.

Read More
Presentations [IO Summit 2022] Implementing MOA-Reflective ADCC & ADCP Cytotoxicity Assays Using Ready-to-Use KILR® Target & Effector Cells from Screening to Lot Release

Jane E. Lamerdin, Ph.D. Vice President, Research & Development Eurofins DiscoverX

Read More
Contact